Bill Guilliouma

Noble Appoints Executive Director of Marketing & Patient Services

By Bill Guilliouma | June 24, 2020
Posted in

Tim McLeroy is an industry pioneer with a groundbreaking career in product development and marketing for global pharmaceutical brands ORLANDO, Fla. (June 24, 2020) – Noble, an Aptar Pharma company,… Read More »

Nemera and Noble Announce Collaboration to Support Patients Who Self-Administer Medication

By Bill Guilliouma | June 16, 2020
Posted in

Nemera, world leader in design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology and generic industries, today announced a collaboration with Noble, the global leader in medical… Read More »

Supporting Improved Patient Onboarding and Adherence With Training Solutions

By Bill Guilliouma | May 28, 2020
Posted in , , , , , , , , , , , , , ,

With more biologics and drug delivery device options entering the market in recent years, pharma companies can decide whether it would be easier for patients to self-inject with an autoinjector… Read More »

Noble Names Aptar Executive to Director of Account Management

By Bill Guilliouma | May 7, 2020
Posted in

Noble Names Aptar Executive to Director of Account Management Newly-created position will focus on representing the customers’ interests and maximizing Noble’s value by bringing solutions to customer challenges ORLANDO, Fla…. Read More »

Telemedicine Gains Acceptance Amid the COVID-19 Pandemic

By Bill Guilliouma | May 5, 2020
Posted in

ORLANDO, Fla. (April 30, 2020) – Telemedicine is poised to become a mainstream alternative to the traditional in-person methods of care delivery, with the COVID-19 pandemic easing barriers to acceptance… Read More »

The Importance of Training and Onboarding for Intranasal Rescue Therapies

By Bill Guilliouma | April 20, 2020
Posted in , , , , , , , ,

Nasal drug repurposing has seen a real resurgence recently, driven by several factors. From an economic perspective, partners benefit from reduced development costs, intellectual property (IP) creation, increased market share… Read More »